Table 2.
NAFLD | Controls | P-value | |
---|---|---|---|
n | 169 | 699 | NA |
Gender(M/F) | 42 / 127 | 179 / 520 | 0.840 |
Age(yrs) † | 56.00(49.00 – 65.50) | 56.00(46.00 – 64.00) | 0.55 |
Body height(cm) | 157.27 ± 8.08 | 156.52 ± 8.08 | 0.288 |
Body weight(kg) | 65.97 ± 10.74 | 53.69 ± 9.22 | 0.000 |
BMI(kg/m2) | 26.59 ± 3.08 | 21.84 ± 2.86 | 0.000 |
SBP(mmHg) | 135.90 ± 21.61 | 125. 49 ± 20.39 | 0.000 |
DBP(mmHg) † | 84.00(78.00 – 92.00) | 80.00(70.00 – 85.00) | 0.000 |
Waist(cm) † | 90.00(84.00 – 95.00) | 75.00(69.00 – 81.00) | 0.000 |
Hip(cm) † | 100.00(95.00 – 103.00) | 91.00(86.75 – 95.00) | 0.000 |
WHR† | 0.90(0.87 – 0.94) | 0.83(0.78 – 0.87) | 0.000 |
FPG(mmol/L) | 6.37 ± 2.09 | 5.71 ± 1.68 | 0.000 |
TG(mmol/L) | 2. 45 ± 1.90 | 1.28 ± 0.99 | 0.000 |
HDLc(mmol/L) † | 1.20(1.02 – 1.49) | 1.60(1.36 – 1.90) | 0.000 |
LDLc(mmol/L) | 2.74 ± 0.93 | 2.64 ± 0.90 | 0.198 |
TC(mmol/L) | 5.69 ± 1.16 | 5.44 ± 1.09 | 0.009 |
ALT(mmol/L) | 36.94 ± 31.83 | 17.88 ± 9.56 | 0.000 |
AST(mmol/L) | 31.72 ± 14.87 | 27.34 ± 10.61 | 0.001 |
GGT(U/L) | 42.54 ± 27.95 | 22.03 ± 13.27 | 0.000 |
ALP(U/L) | 83.43 ± 28.03 | 75.99 ± 24.98 | 0.002 |
FINS(mlU/L) † | 10.66(7.80 – 14.52) | 5.05(3.39 – 7.34) | 0.000 |
HOMA-IR † | 2.84(2.03 – 4.03) | 1.20(0.80 – 1.83) | 0.000 |
HSCRP(mg/L) † | 1.00(1.00 – 2.32) | 1.00(1.00 – 2.30) | 0.472 |
ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; FINS, fasting insulin; GGT, gamma-glutamyl transpeptidase; HDLc, high-density lipoprotein cholesterol; HOMA-IR, homoeostatic metabolic assessment insulin resistance index; HSCRP, high sensitive C-reactive protein; LDLc, low-density lipoprotein cholesterol; NA, not analyzed; NAFLD, non-alcoholic fatty liver disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; WHR, waist-to-hip ratio.
Continuous data with skewed distribution